Ontology highlight
ABSTRACT: Background
We have developed a novel approach to categorize immunity in patients that uses a combination of whole blood flow cytometry and hierarchical clustering.Methods
Our approach was based on determining the number (cells/?l) of the major leukocyte subsets in unfractionated, whole blood using quantitative flow cytometry. These measurements were performed in 40 healthy volunteers and 120 patients with glioblastoma, renal cell carcinoma, non-Hodgkin lymphoma, ovarian cancer or acute lung injury. After normalization, we used unsupervised hierarchical clustering to sort individuals by similarity into discreet groups we call immune profiles.Results
Five immune profiles were identified. Four of the diseases tested had patients distributed across at least four of the profiles. Cancer patients found in immune profiles dominated by healthy volunteers showed improved survival (p?ConclusionsComprehensive multi-factorial immune analysis resulting in immune profiles were prognostic, uncovered relationships among immune markers and identified a potential biomarker for the prognosis of cancer. Immune profiles may be useful to streamline evaluation of immune modulating therapies and continue to identify immune based biomarkers.
SUBMITTER: Gustafson MP
PROVIDER: S-EPMC4266565 | biostudies-literature | 2013
REPOSITORIES: biostudies-literature
Gustafson Michael P MP Lin Yi Y LaPlant Betsy B Liwski Courtney J CJ Maas Mary L ML League Stacy C SC Bauer Philippe R PR Abraham Roshini S RS Tollefson Matthew K MK Kwon Eugene D ED Gastineau Dennis A DA Dietz Allan B AB
Journal for immunotherapy of cancer 20130627
<h4>Background</h4>We have developed a novel approach to categorize immunity in patients that uses a combination of whole blood flow cytometry and hierarchical clustering.<h4>Methods</h4>Our approach was based on determining the number (cells/μl) of the major leukocyte subsets in unfractionated, whole blood using quantitative flow cytometry. These measurements were performed in 40 healthy volunteers and 120 patients with glioblastoma, renal cell carcinoma, non-Hodgkin lymphoma, ovarian cancer or ...[more]